| Purpose | Sentis Non-Invasive Lung Cancer Panel (ctDNA, 13 Genes) Test that enables highly accurate mutation detection across most clinically relevant genes associated with lung cancer. The panel allows highly sensitive detection of actionable mutations in 13 genes* from liquid biopsy samples (ctDNA), providing a comprehensive molecular profiling of lung cancer for clinicians.Genes: BRCA1, BRCA2, CHEK2, HOXB13, MSH2, MSH6, PMS2, MLH1, ATM, BRIP1, PALB2, MRE11A, NBN, RAD51C, RAD51D, ATR, FAM175A, GEN1, MUTYH, TP53, EPCAM, FANCA, CDK12 (*13 genes out of 20 can be sequenced from ctDNA). |
| Test Code | DX1459 |
| Turnaround Time (TAT) | 20 Days |
| Sample Tested | Sentis Non-Invasive Lung Cancer Panel (ctDNA, 13 Genes) - ≥10mL of peripheral blood (separated plasma and formed elements) OR
- ≥8mL of peripheral blood collected in Streck Cell-Free DNA BCT® tube
|
| Methodology | - DNA Extraction and QC.
- Targeted Capture of 13 genes associated with Lung Cancer from liquid biopsy samples (ctDNA).
- Highly sensitive detection of actionable mutations from liquid biopsy samples (ctDNA) in 13 genes associated with lung cancer.
- Reports having information for targeted drugs (Precision Medicine).
- Genetic Counselling.
|
| Advantages | - All exons plus flanking intronic regions covered for all genes tested (13 genes associated with lung cancer); one single assay that detects point mutations, deletions, insertions, duplications, rearrangements.
- A streamlined sample-to-results workflow with MGI’s platform and automated on-premises NGS bioinformatics system, enabling effortless obtainment of insightful reports from samples. .
- Providing molecular evidence for the consideration of more than 42 targeted therapies (Precision Medicine).
- Liquid biopsy allows genetic profiling in situations where tissue biopsy is not available or continuous monitoring of tumor molecular profile is required.
- 4000X coverage (ctDNA).
|
